Clinical Trial

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Protocol Amendment History 2 changes
notable Enrollment increased: 352 -> 426 participants 2026-07-30
notable Trial sites expanded: 141 -> 145 locations 2026-06-26
Trial Details
NCT Number NCT07011745
Lead Sponsor Bristol-Myers Squibb
Conditions Alzheimer's Disease
Enrollment 426 participants
Start Date 2025-07-16
Primary Completion 2028-11-03 (estimated)
Study Completion 2028-11-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-29